Controlled Access Programme (CAP) for the United Kingdom
As part of the conditions of Marketing Authorisation, the Marketing Authorisation Holder (UCB Pharma Ltd, UCB Pharma S.A.) is required to implement a controlled access programme (CAP).
A controlled access programme has been created to:
- prevent off-label use in weight management
- confirm that prescribing physicians have been informed of the need for periodic cardiac monitoring in patients taking Finteplaâ–¼ (fenfluramine).
IMPORTANT
In order for Fintepla prescriptions to be fulfilled and dispensed in pharmacy, the prescriber must provide a unique identification (ID), called a Prescriber ID to the prescription. Failure to do this will mean the pharmacy will be unable to dispense Fintepla.
Follow the steps below to obtain your unique Prescriber ID:
- Complete form with your professional details
- Read the educational content & attest (approx. 2 mins)
- Receive & Save Your Prescriber ID
- Learn how to use your Prescriber ID to prescribe fenfluramine
Click below to download materials